BioModels’ Post

Characterizing new drug models/endpoints? Or searching for translatable models of human disease? Hear from Dr. Andrew Borkowski & Dr. Nicole Smith as they discuss selection of preclinical models for inflammatory diseases including, Inflammatory Bowel Disease (IBD)/colitis, GvHD and pulmonary disease. Learn more & register here: https://bit.ly/3SYgKrY Thank you to Biomodels, LLC for making this webinar possible! #Preclinical #Inflammation #InflammatoryDisease

More than 40% of IBD patients fail to respond to therapy. This is a major problem, as IBD can be a debilitating disease. There is an unmet need for high-quality human data to help drug developers identify effective IBD therapies. We understand that most physiologically-relevant and human-derived systems are not cost effective, take time and are not reproducible. Acknowledging this we have developed IntegriGut Screen Efficacy - a rapid, reprodcible and physiologically relevant screening platform based on patient-derived organoids. Are you interested in learning more about IntegriGut Screen Efficacy? Click on the link below to learn more. #patientinthelab #organoids #IBD #inflammation #inflammatoryboweldisease #guthealth #digestivedisease

🎉 We are excited to announce our collaboration with Eli Lilly and Company to support the development of a QIAstat-Dx IVD panel that identifies patients at risk for developing #Alzheimer’s disease. Learn more 👉 https://lnkd.in/eR-87PsM ✅ We are developing the first QIAstat-Dx IVD panel for neurodegenerative applications. ✅ The new panel will identify APOE genotypes, one of many factors considered in the diagnosis of patients with Alzheimer’s disease. ✅ This collaboration marks a significant milestone, as the QIAstat-Dx panel will be the first commercially available in-vitro diagnostic for APOE genotyping.

Exciting to follow the development of IVD tools for neurodegenerative diseases in the coming years.

Early diagnosis can help a biopharmaceutical approach to early treatment strategies.

A cystic fibrosis diagnosis once meant a life expectancy only through early adulthood. However, thanks to the development of therapeutics that target the CFTR proteins responsible for this disease, CF patients can now expect to live significantly longer than before. In a recent article exploring treatment options for #CF, our very own trial manager with extensive experience in this space, Nadia Shive, shared her insights on these vital therapies, challenges in cystic fibrosis clinical trials, and more in Labiotech.eu. Read the full article here: https://lnkd.in/eTnC5VEU #respiratoryhealth #cysticfibrosis #cysticfibrosismarket #clinicaltrials

Fight Back, Not Back Down: How Personalized Digital Therapeutics Empower You in the Face of Neurodegenerative Diseases The diagnosis of a neurodegenerative disease can feel like a heavy blow, a sentence to a passive existence, waiting for the inevitable progression. But what if the future held a different story? One where you, not the disease, are in the driver's seat? Enter personalized digital therapeutics (PDT), a revolutionary approach transforming the fight against these challenging conditions. Learn more at https://lnkd.in/eXe9p-kh #digitaltherapeutics #parkinsons #dementiacare

Vazyme is dedicated to advancing clinical diagnosis for Alzheimer’s Disease (AD) by providing highly sensitive blood test solutions for patients and those concerned about AD. Our self-developed blood testing solutions based on six key blood biomarkers, Aβ40, Aβ42, p-Tau181, p-Tau217, NFL, and GFAP, offer advantages of High Specificity, High Affinity and High Efficacy, enhancing the accuracy and efficiency of the diagnostic process. This groundbreaking development represents a significant step forward in the fight against this challenging condition, providing earlier and more reliable detection of AD and then allowing more time for treatment. Take a closer look at Vazyme AD detection solutions as below. And check our story about what we do to save memories>> https://bit.ly/4e7iUPa #AlzheimersAwareness #Vazyme #ProtectMemories #EarlyDetection

Tomorrow, we will be exploring the role of imaging biomarkers in MS research and how it will enable us to understand this disease progression and treatment at a patient level. Join us on April 10th as Frederik Barkhof, and Lynne Hughes discuss the following: Webinar Topics: ➡️ Insights into the intricate world of MS drug development ➡️ Established and emerging imaging techniques for diagnostic, disease management, and clinical trial purposes ➡️ Your Questions Answered Webinar Details: 📅 Date: Wednesday, April 10th 2024 🕓 Time: 3pm BST / 4pm CET / 10am EDT Link to register: https://lnkd.in/exqkdu4e Register to reserve your spot or get the recording in-case you miss out. Know someone who could benefit from our insight? Forward this post to them!

Read BioStock - Connecting Innovation and Capital's interview with our CEO, Ellen Donnelly, including comments on the first quarter, the recent financing round, and the upcoming interim analysis in the ongoing FALCON study: "I am confident that we have designed a study that will properly test the safety and efficacy of KL1333 in patients with primary mitochondrial disease." Read the full interview by following the link below: #mitochondrialdisease #mito #q1 #drugdevelopment https://lnkd.in/d4CqS3yF